1st Circ. Won't Revive Karyopharm Investors' Stock-Drop Suit
The First Circuit won't revive a putative securities fraud class action claiming that Karyopharm Therapeutics Inc. executives gave an overly rosy assessment of negative drug trial results, ruling Friday that investors...To view the full article, register now.
Already a subscriber? Click here to view full article